Norak Biosciences

Norak Biosciences was a biotechnology company specializing in the discovery and development of therapeutic compounds targeting G protein-coupled receptors (GPCRs). The company's core value was centered on its proprietary Transfluor technology, a universal screening platform licensed from Duke University that allowed for the identification of drug candidates across the entire GPCR family. This technology was particularly notable for its ability to screen orphan GPCRs and monitor receptor desensitization and internalisation via arrestin translocation. Norak's business model included both internal drug discovery programs and the licensing of its Transfluor technology to major pharmaceutical companies. In 2003, the company was acquired by Arena Pharmaceuticals to bolster their GPCR-focused pipeline and screening capabilities.